MedTrace Logo

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

NCT03804255 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-05-06

No results posted yet for this study

Summary

This trial assesses current biomarker testing practices for common solid cancers in precision oncology in the community setting. Cancer biomarkers are used for diagnosing the disease, determining prognosis, predicting response to a targeted therapy, or monitoring response to therapy. Testing quality, including accuracy and timeliness, is imperative for correct disease prognosis and identification of patients who may or may not benefit from a targeted therapy. Assessing current biomarker testing practices may help doctors identify gaps and variations in testing as well as on potential ?best practices? that may be informative and generalizable to community oncology programs.

Conditions

  • Breast Carcinoma
  • Colorectal Carcinoma
  • Community Practice
  • Lung Carcinoma
  • Melanoma
  • Solid Neoplasm

Interventions

OTHER

Survey Administration

Complete surveys

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Julia Trosman · ECOG-ACRIN Cancer Research Group

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-08
Primary Completion
2020-05-29
Completion
2020-05-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03804255 on ClinicalTrials.gov